Rare Endocrine Disorders
Explore facts and recommendations for pharmacological treatments for rare endocrine disorders.
We didn't find any resources that match your selection.
Please adjust your filter(s) and try again.
Somapacitan vs. Once-daily Growth Hormone - Phase 3 Pediatric Patients with Growth Hormone Deficiency (REAL 4)
This video discusses the REAL4 trial, the pivotal Phase 3 trial investigating efficacy and safety of once-weekly somapacitan compared to once daily growth hormone (GH) in growth-hormone-naïve pre-pubertal children with GH deficiency.
Somapacitan vs. Once-daily Growth Hormone - Phase 3 Pediatric Patients with Growth Hormone Deficiency (REAL 4)
Results of REAL 4, the pivotal Phase 3 trial investigating efficacy and safety of once-weekly somapacitan compared to once daily growth hormone (GH) in growth-hormone-naïve pre-pubertal children with GH deficiency.
Somapacitan Mechanism of Action
This video discusses the mechanism of action of somapacitan.
Somapacitan vs. Once-daily Growth Hormone - Phase 2 Pediatric Patients with Growth Hormone Deficiency (REAL 3)
Overview of REAL 3, the Phase 2 dose-finding trial investigating efficacy and safety of once-weekly somapacitan compared to once daily growth hormone (GH) injection in growth-hormone naïve pre-pubertal children with GH deficiency.
Somapacitan Treatment-naive Adults with Growth Hormone Deficiency (REAL 1)
Summary of REAL 1, the pivotal Phase 3 study evaluating the efficacy and safety of once-weekly somapacitan compared to once-weekly placebo or once-daily growth hormone in adults with growth hormone deficiency.
Albumin Interactions with Somapacitan
An overview of expected albumin interactions from hypoalbuminemia or other protein-bound drugs based on the mechanism of protraction (albumin-binding) used by somapacitan.
Continuing Education
Find accredited opportunities in rare endocrine education.
Rare Endocrine Disorders
Rare Endocrine Disorders
Looking for additional resources?
Explore other libraries or search the Exchange.
Additional Information
Speak to a live medical representative.
If you are a healthcare provider from the United States, click below to request information directly from the Novo Nordisk Medical Information department. If you are a patient, please visit here to contact us, or call 1-800-727-6500.
Search the Medical Information Database
The Scientific Exchange is a resource for U.S. Healthcare Professionals to learn more about disease states investigated by Novo Nordisk and our related products.
Scientific Exchange is a trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.
